BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 05, 2004
 |  BioCentury  |  Finance

2Q approvals

2Q approvals

2Q approvals
Selected second quarter product approvals.
Company Approval
Amgen (AMGN)/Wyeth (WYE) Europe approves expanded label for Enbrel etanercept in combination with methotrexate to treat rheumatoid arthritis (RA).
Biogen Idec (BIIB) Australia approves Amevive alefacept to treat moderate to severe chronic plaque psoriasis.
Biovail (TSE:BVF; BVF) FDA approves Cardizem LA to treat chronic, stable angina.
Cephalon (CEPH) U.K. approves expanded label for Provigil to treat excessive sleepiness.
Indevus (IDEV)/Pliva (LSE:PLVD) FDA approves Sanctura trospium to treat overactive bladder (OAB).
Ista (ISTA) FDA approves Vitrase ovine hyaluronidase for...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >